Using Diosmin and Hesperidin to Treat Rheumatoid Arthritis
Clinical Study Evaluating the Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
This study is testing if a combination of two natural compounds, diosmin and hesperidin, can help people with rheumatoid arthritis by reducing inflammation and protecting their liver while they take their usual medication.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 19 Years to 65 Years |
| Sex | All |
| Sponsor | Alexandria University Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Alexandria) |
| Trial ID | NCT05756179 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of a combination of flavonoids, diosmin and hesperidin, as an adjuvant therapy for patients with rheumatoid arthritis. It focuses on assessing the anti-inflammatory and antioxidant properties of these compounds, alongside clinical and functional evaluations of disease activity. Additionally, the study aims to investigate the hepatoprotective effects of the treatment against liver adverse events caused by methotrexate, a common medication for rheumatoid arthritis.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with mild to moderate rheumatoid arthritis.
Not a fit: Patients who are pregnant, lactating, or have liver or renal impairment, as well as those on specific biological therapies, may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new, effective option for managing rheumatoid arthritis symptoms and reducing liver toxicity from existing medications.
How similar studies have performed: While the use of flavonoids in treating inflammatory conditions is promising, this specific combination has not been extensively tested in similar studies, making it a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with mild to moderate disease activity. * Patient age must be more than 18 years. Exclusion Criteria: * Pregnant and lactating females. * Patients with liver, renal impairment or any other inflammatory diseases. * Patients on TNF-α (tumor necrosis factor- α) or IL-1β (interleukin-1β) antagonists.
Where this trial is running
Alexandria
- Alexandria university hospital — Alexandria, Egypt (Recruiting)
Study contacts
- Principal investigator: AHMED ABDELBAR, MSc — College of Pharmacy - Arab Academy for Science and Technology
- Study coordinator: AHMED ABDELBAR, MSc
- Email: dr.ahmed_post@yahoo.com
- Phone: 00201021914588
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.